Delpazolid (LCB01-0371)

Class: Oxazolidinone

Spectrum of activity:	Gram-positive
Details of activity:	Bacterial infections
Institute where first reported:	LegoChem Biosciences (South Korea)
Year first mentioned:	2010
Highest developmental phase:	Phase 2 (NCT05225558; NCT06004037)
Development status:	Active
Reason Dropped:	NCT05225558 Clinical Trial terminated due to issues with enrolling subjects.

Chemical structure(s):
Canonical SMILES:	CN1CCN(C=N1)C2=CC=C(C=C2F)N3C[C@H](CO)OC3=O
Isomeric SMILES:	CN1CCN(C=N1)C2=C(C=C(C=C2)N3C[C@@H](OC3=O)CO)F
InChI:	InChI=1S/C14H17FN4O3/c1-17-4-5-18(9-16-17)13-3-2-10(6-12(13)15)19-7-11(8-20)22-14(19)21/h2-3,6,9,11,20H,4-5,7-8H2,1H3/t11-/m1/s1
InChI Key:	QLUWQAFDTNAYPN-LLVKDONJSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/44205191

External links:
Guide to Pharmacology:	delpazolid
Main Source:	http://www.legochembio.com/m/eng/board_skin/board_view.asp?idx=406&page=1&bbs_code=13&key=0&word=&etc=
Citations:	http://aac.asm.org/content/54/12/5359.full https://www.researchgate.net/publication/325198402_Delpazolid_Oxazolidinone_antibiotic_Treatment_of_tuberculosis